about
Fragmenting the S100B-p53 interaction: combined virtual/biophysical screening approaches to identify ligandsAn integrated computational approach to rationalize the activity of non-zinc-binding MMP-2 inhibitorsIdentification of small molecules acting against H1N1 influenza A virus.Identification of new anti-Candida compounds by ligand-based pharmacophore virtual screening.An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13.Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus.Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors.Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.Ac-tLeu-Asp-H is the minimal and highly effective human caspase-3 inhibitor: biological and in silico studies.Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies.Amino Acid derivatives as new zinc binding groups for the design of selective matrix metalloproteinase inhibitors.Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption.Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.Synthesis and evaluation of new tripeptide phosphonate inhibitors of MMP-8 and MMP-2.Catechol-based matrix metalloproteinase inhibitors with additional antioxidative activity.AMBER force field implementation of the boronate function to simulate the inhibition of beta-lactamases by alkyl and aryl boronic acids.Effects of biphenyl sulfonylamino methyl bisphosphonic acids on Porphyromonas gingivalis and cytokine secretion by oral epithelial cells.N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.Dual targeting of cancer-related human matrix metalloproteinases and carbonic anhydrases by chiral N-(biarylsulfonyl)-phosphonic acids.Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors.Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitorsα-Biphenylsulfonylamino 2-methylpropyl phosphonates: Enantioselective synthesis and selective inhibition of MMPsBovine Lactoferrin Prevents Influenza A Virus Infection by Interfering with the Fusogenic Function of Viral HemagglutininIn vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnoverInvestigation of the N-BP Binding at FPPS by Combined Computational ApproachesBisphosfonate matrix metalloproteinase inhibitors for the treatment of periodontitis: An in vitro studyNovel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesisBone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy
P50
Q27658965-1445A9A4-E103-4F66-821E-38D9D76D292CQ28485109-2F326B46-2B7D-4A38-AE77-8C88041AC83FQ35865796-97EF2455-E7DD-4D42-9823-19F5EE22379DQ35960473-3ABAB2F2-D832-4864-9E4D-BD6C91672D72Q36043034-FC79B3BB-B7C5-412A-8819-A36C170A86A8Q36078299-008372CD-4529-477A-92F7-D4EF5B84097CQ37726584-675AD4FF-1129-4BAF-96B4-88E2533156B7Q38316935-BDB77955-E096-4160-BB84-CAFCD6E2433CQ38565628-064ABFDA-429F-40A6-8A7E-F871FBF4999EQ38946472-7DDC58B8-73FC-4F27-9DCC-CC270EBDE729Q39091093-1C3A229C-5131-4939-B7AB-CB210ECD44CDQ39249230-612F1F0C-9B80-4F52-A65B-BB24F536A33DQ39306263-C816CC9C-46A5-4ACB-9771-DFB8B786765FQ39516147-7DE794AA-C7E6-430B-B3F8-77BABD81C065Q40054877-07ECD2DE-6302-40D0-AB6B-48E8480FE77BQ43624351-E62A76D3-829E-4A08-8888-51855BFABEFDQ45278421-172CDE7B-1877-46E7-98DB-E2FEBCACC209Q46497632-BE086E67-6DE1-44D1-B03A-16B527DA7B0DQ46695485-2B440FDE-4F84-4439-A64B-F66DC188B35EQ46741439-9F3F4D54-E666-4746-AA52-DAAE33C3BBCBQ46768146-4E627C9C-4F29-4849-AF23-04C6408AFC86Q46922525-EFE60CC9-4DC1-4F81-9F25-F689A2EDD516Q47742715-02DF4059-D374-4A9E-AC0D-0476D989095CQ51830769-AF924BE6-5CCE-42A0-B193-7F92EF470E96Q58308225-EB1E8998-90E3-4676-82DC-7667AA3F8F21Q58308254-D8711AE3-C5F3-4237-A926-DC4D54629661Q61797242-30FC0CE7-531A-4A9D-B1C0-358939F1F599Q62831991-34E6E434-0351-4AF6-B7C6-BE1638CBC25AQ62832074-05C80B13-6A85-475A-AAE2-433E38AB9770Q88539810-C16CB4D4-72E0-451C-92ED-44FD31A75FE6Q91451506-87B8A7CB-6451-43DA-A8B5-4418788E8C49Q96125401-C6B4DDA5-79CA-4598-8413-0DD3221C08F9
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mariangela Agamennone
@ast
Mariangela Agamennone
@en
Mariangela Agamennone
@es
Mariangela Agamennone
@nl
Mariangela Agamennone
@sl
type
label
Mariangela Agamennone
@ast
Mariangela Agamennone
@en
Mariangela Agamennone
@es
Mariangela Agamennone
@nl
Mariangela Agamennone
@sl
prefLabel
Mariangela Agamennone
@ast
Mariangela Agamennone
@en
Mariangela Agamennone
@es
Mariangela Agamennone
@nl
Mariangela Agamennone
@sl
P106
P1153
6506766137
P21
P31
P496
0000-0001-5198-0051